Intravenous dantrolene for class iii antiarrhythmic drug resistant refractory ventricular arrhythmias in patients with heart failure: final results of a phase ii study

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Doctor Junya Nawata

Yamaguchi University Graduate School of Medicine, Ube (Japan)

5 More presentations in this session

Presentation thumbnail

Sudden cardiac death in young adults: a contemporary 5 year observational cohort study from a tertiary cardiology center

Doctor T. Barboi (Bucharest, RO)

Presentation thumbnail

Electrocardiographic features associated with genetic positivity in brugada syndrome

Doctor B. Lage Garcia (Guimaraes, PT)

Presentation thumbnail

Catheter ablation to reduce cardiovascular hospitalizations in patients with ventricular arrhythmias: a systematic review and meta-analysis of randomized controlled trials

Doctor M. Grine (Coimbra, PT)

Presentation thumbnail

Real-world performance of current sudden cardiac death risk stratification tools in hypertrophic cardiomyopathy: a single-centre study

Doctor H. Santos Moreira (Porto, PT)

Presentation thumbnail

Real-world applicability of a risk prediction score in apical hypertrophic cardiomyopathy

Doctor H. Santos Moreira (Porto, PT)

Access the full session

Session thumbnail

Sudden cardiac death, ventricular arrhythmias, and emerging treatment strategies

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Session

Ventricular storm (2)

Webinar

The role of cardiac magnetic resonance for patients with ventricular arrhythmias and the prevention of sudden cardiac death in light of the 2022 ESC Guidelines

Congress Session

Ventricular tachycardia ablation in challenging scenarios: case-based management strategies

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources